ZOSTAVAX™ in Patients on Chronic/Maintenance Corticosteroids (V211-017) (COMPLETED)

PHASE2CompletedINTERVENTIONAL

Enrollment

309

Participants

Timeline

Start Date

October 31, 2007

Primary Completion Date

August 31, 2010

Study Completion Date

August 31, 2010

Conditions

Herpes Zoster

Interventions

BIOLOGICAL

Zoster Vaccine, Live

A single dose of 0.65 ml Zoster Vaccine, Live, injected subcutaneously on Day 1

BIOLOGICAL

Comparator: Placebo

A single dose of 0.65 ml Placebo to ZOSTAVAX™ injected subcutaneously on Day 1.

All Listed Sponsors

lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00546819 - ZOSTAVAX™ in Patients on Chronic/Maintenance Corticosteroids (V211-017) (COMPLETED) | Biotech Hunter | Biotech Hunter